-
Courses
Courses
Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
-
University Life
University Life
Each year more than 4,000 choose University of Galway as their University of choice. Find out what life at University of Galway is all about here.
-
About University of Galway
About University of Galway
Since 1845, University of Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
-
Colleges & Schools
Colleges & Schools
University of Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a range of key areas of expertise.
-
Research & Innovation
Research & Innovation
University of Galway’s vibrant research community take on some of the most pressing challenges of our times.
-
Business & Industry
Guiding Breakthrough Research at University of Galway
We explore and facilitate commercial opportunities for the research community at University of Galway, as well as facilitating industry partnership.
-
Alumni & Friends
Alumni & Friends
There are 128,000 University of Galway alumni worldwide. Stay connected to your alumni community! Join our social networks and update your details online.
-
Community Engagement
Community Engagement
At University of Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
November 2015 NUI GALWAY RESEARCH COULD HELP IN DEVELOPING A NEW THERAPY FOR METASTATIC CANCER
NUI GALWAY RESEARCH COULD HELP IN DEVELOPING A NEW THERAPY FOR METASTATIC CANCER
Journal publishes results of Irish and European research study related to drug discovery for metastatic cancer
Researchers from the School of Chemistry and School of Natural Sciences at NUI Galway, and Warsaw University of Life Sciences have worked together on a study that could help in the development of a new therapy for metastatic cancer. Their work was published today (6 November 2015), in Chemistry A European Journal, and features as the front cover article.
Metastatic cancer occurs when tumour cells migrate or metastasise from a primary tumour to other sites leading to secondary tumours, and this is the main cause of death from cancer. Synthesis is used by chemists to build compounds or materials for wide ranging applications. This study has involved NUI Galway researchers working out synthesis pathways to new analogues of migrastatin as potential blockers of metastasis or tumour cell migration. The researchers showed that some of the new compounds, such as MGSTA-6, exhibited the ability to block tumour cell migration in the laboratory.
Professor Paul Murphy, Head of the School of Chemistry at NUI Galway, and his team collaborated with Corrado Santocanale, Professor of Molecular Medicine from the School of Natural Sciences at NUI Galway. Professor Santocanale’s core research is related to cancer therapeutics and an assay for this research was established in his laboratory. Professor Magdalena Krol and her team from the Warsaw University of Life Sciences also contributed to the research through a biological study of the compounds prepared. The latter collaboration came about as a result of a COST Networking Action, StemChem, where both Professor Murphy and Professor Krol are members.
Professor Paul Murphy said: “The research demonstrates the value of Synthetic Chemistry, which can be used to produce compounds not made by Nature and which instead are inspired by Nature. This provides valuable new compounds for drug discovery projects. The research shows the importance of chemists working together with cancer biologists to investigate properties of newly generated products.”
The first author of the article, Dr Daniele Lo Re, a researcher with Professor Murphy’s team at NUI Galway, explains, “One of the compounds synthesised, MGSTA-6, showed evidence that it has a low risk of displaying adverse side effects.”
The research to isolate migrastatin, a structurally complex natural product, first occurred in the early 2000’s in Japan, and this initially highlighted the potential of this natural product as a blocker of metastasis. Subsequently research from the Samuel Danishefsky Laboratory at Memorial Sloan Kettering Cancer Centre in New York led to the finding that simpler migrastatin analogues could inhibit tumour metastasis in the laboratory.
This research study was funded by Science Foundation Ireland (SFI), the European Regional Development Fund, Poland’s National Science Centre, the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme and COST (a European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe).
To view the paper visit: http://dx.doi.org/10.1002/chem.201502861
-Ends-
Featured Stories
HSE West North West- University of Galway Cancer Network receives European accreditation
New study unveils key insights into muscle atrophy during space flight
ENLIGHT European University alliance supports 12 projects at University of Galway
Press Office
+353 (0) 91 493361
Follow @nuigalwaypress